Across TCGA pan-cancer cohorts, CYP26C1 RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated CYP26C1 data layer compared with 3 for mutation status.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CYP26C1 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated CYP26C1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and COAD show a favorable association.
HNSC, BLCA, and READ are the cancer types where CYP26C1 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.